Press Release

NeoGenomics Announces Pricing of $9.5 Million Public Offering

NeoGenomics Reports 181% Increase in Adjusted EBITDA on 38% Revenue Growth and Achieves Profitability in 2012

NeoGenomics Schedules its Q4 and Full Year 2012 Earnings Release for February 14, 2013

NeoGenomics Validates and Launches NeoSITE™ Barrett's Esophagus FISH Test for Surveillance and Diagnosis of High Grade Dysplasia/Esophageal Cancer

NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter

NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients